Banales, Jesus M. http://orcid.org/0000-0002-5224-2373
Marin, Jose J. G. http://orcid.org/0000-0003-1186-6849
Lamarca, Angela http://orcid.org/0000-0001-9696-6122
Rodrigues, Pedro M. http://orcid.org/0000-0001-6193-7436
Khan, Shahid A.
Roberts, Lewis R. http://orcid.org/0000-0001-7885-8574
Cardinale, Vincenzo
Carpino, Guido http://orcid.org/0000-0001-8570-2519
Andersen, Jesper B. http://orcid.org/0000-0003-1760-5244
Braconi, Chiara http://orcid.org/0000-0003-4835-1259
Calvisi, Diego F.
Perugorria, Maria J.
Fabris, Luca http://orcid.org/0000-0001-8538-6317
Boulter, Luke http://orcid.org/0000-0002-7954-6705
Macias, Rocio I. R. http://orcid.org/0000-0002-4748-0326
Gaudio, Eugenio
Alvaro, Domenico
Gradilone, Sergio A.
Strazzabosco, Mario http://orcid.org/0000-0002-1995-6331
Marzioni, Marco
Coulouarn, CĂ©dric
Fouassier, Laura http://orcid.org/0000-0001-6377-5610
Raggi, Chiara
Invernizzi, Pietro http://orcid.org/0000-0003-3262-1998
Mertens, Joachim C.
Moncsek, Anja
Ilyas, Sumera I.
Heimbach, Julie
Koerkamp, Bas Groot http://orcid.org/0000-0003-1917-6973
Bruix, Jordi
Forner, Alejandro http://orcid.org/0000-0002-9014-4950
Bridgewater, John http://orcid.org/0000-0001-9186-1604
Valle, Juan W. http://orcid.org/0000-0002-1999-0863
Gores, Gregory J. http://orcid.org/0000-0003-3151-009X
Article History
Accepted: 29 April 2020
First Online: 30 June 2020
Competing interests
: A.L. received travel and educational support from Ipsen, Pfizer, Bayer, AAA, Sirtex, Novartis, Mylan and Delcath; speaker honoraria from Merck, Pfizer, Ipsen and Incyte; and advisory honoraria from EISAI, Nutricia and QED; she is also a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. J.W.V. declares consulting or advisory roles for Agios, AstraZeneca, Delcath Systems, Keocyt, Genoscience Pharma, Incyte, Ipsen, Merck, Mundipharma EDO, Novartis, PCI Biotech, Pfizer, Pieris Pharmaceuticals, QED and Wren Laboratories; Speakers’ Bureau for Imaging Equipment Limited, Ipsen, Novartis and Nucana; and travel grants from Celgene and Nucana. J. Bridgewater declares consulting or advisory roles for Merck Serono, SERVIER, Roche, Bayer, AstraZeneca, Incyte and Basilea; travel support from MSD Oncology, Merck Serono, Servier and BMS. J.M.B. is scientific advisor to OWL Metabolomics. M.M. is speaker for Intercept Pharma and advisor to IQVIA srl and Simon & Cutcher Ltd. M.S. is a member of the Advisory Board for Bayer, Esiai/Merk and Engitix. A.F. received lecture fees from Bayer, Gilead and MSD; and consultancy fees from Bayer, AstraZeneca and Guerbert. J. Bruix received consultancy lecture fees from Bayer, Gilead and MSD; consultancy fees from Bayer, AstraZeneca and Guerbert; research grants from Bayer, BTG; educational grants from Bayer, BTG; conferences fees from Bayer, BTG and Ipsen; and fees for talks from Bayer-Shering Pharma, BTG- Biocompatibles, Eisai, Terumo, Sirtex and Ipsen. P.I. receives funding from AMAF Monza ONLUS and AIRCS. The remaining authors declare no competing interests.